Besides, a startup needs to be aged 11-15 years to get the investment from the fund. Among the most successful fund investment fields, there are Pharmaceutical, Medical Device. Among the various public portfolio startups of the fund, we may underline Clinicient, Sapphire Digital, Xenex The fund has no exact preference in a number of founders of portfolio startups.
The standard case for the fund is to invest in rounds with 4 partakers. Despite the Piper Jaffray Merchant Banking, startups are often financed by Greycroft, Targeted Technology Fund, Shumway Capital. The meaningful sponsors for the fund in investment in the same round are Greycroft, Telegraph Hill Partners, Tectonic Ventures. In the next rounds fund is usually obtained by Goldman Sachs.
The important activity for fund was in 2019. Considering the real fund results, this Corporate Investor is 40 percentage points more often commits exit comparing to other organizations. The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in less than 2 deals per year.
Related Funds
| Fund Name | Location |
| Atlassian Ventures | Australia, New South Wales, Sydney |
| C&D Co. | - |
| Chione | Berlin, Berlin, Germany |
| FirstGen Capital | Australia, New South Wales, Sydney |
| High Peak Capital | - |
| Huaan Securities | Anhui, China, Hefei |
| Infinity Venture Fund | - |
| Insignia Capital Group | California, United States, Walnut Creek |
| Lannebo Fonder | Stockholm, Stockholm County, Sweden |
| M7 Real Estate | England, London, United Kingdom |
| Nanjing Wuxiang Zichan | China, Jiangsu, Nanjing |
| Noorfund | - |
| Orbis Investment Management | Bermuda, Hamilton |
| R Ventures | Stockholm, Stockholm County, Sweden |
| Regenerative Medicine Minnesota | Minnesota, Minnesota City, United States |
| Tsinghua Innovation Ventures | Beijing, China, Haidian |
| Venture Cap TV | Canada, Montréal, Quebec |
| Yingke Capital | China, Fuzhou, Jiangxi |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Integrity Orthopaedics | $20M | 30 Apr 2024 | Maple Plain, Minnesota, United States | ||
Moxe Health | $30M | 01 Jun 2022 | Madison, Wisconsin, United States | ||
Paragon 28 | 14 Aug 2020 | Colorado, United States | |||
Elligo Health Research | $20M | 07 May 2019 | Austin, Texas, United States | ||
Foodsby | $13M | 20 Aug 2018 | Minneapolis, Minnesota, United States | ||
Sapphire Digital | $22M | 18 Jun 2013 | New Jersey, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Integrity Orthopaedics | $20M | 30 Apr 2024 | Maple Plain, Minnesota, United States | ||
Moxe Health | $30M | 01 Jun 2022 | Madison, Wisconsin, United States | ||
Paragon 28 | 14 Aug 2020 | Colorado, United States | |||
Elligo Health Research | $20M | 07 May 2019 | Austin, Texas, United States | ||
Foodsby | $13M | 20 Aug 2018 | Minneapolis, Minnesota, United States | ||
Sapphire Digital | $22M | 18 Jun 2013 | New Jersey, United States |
